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Regulation of serum hepcidin levels in sickle cell
disease
The peptide hormone hepcidin exerts its function by
binding to the transmembrane cellular iron exporter fer-
roportin and inducing its internalization and degrada-
tion, resulting in decreased intestinal iron uptake and
iron retention in the reticulo-endothelial (RE)
macrophages. Inflammatory cytokines and iron loading
increase hepcidin production, while increased bone
marrow activity, and anemia suppress hepcidin synthe-
sis.1,2 However, most of the evidence of these regulato-
ry processes is obtained by molecular in vitro work and
mice models, and much is still unknown about how
these different stimuli interact in man. 
Sickle cell disease (SCD) patients are characterized by
chronic hemolytic anemia, increased erythropoiesis and
a chronic inflammatory state with endothelial activation
and enhanced red cell and leukocyte adhesion. Sickle
cell patients have iron overload due to chronic blood
transfusions in the treatment or prevention of the severe
sickle cell-related complications such as stroke.3 SCD
has been associated with low urinary hepcidin levels in
children.4 However, serum hepcidin 25-amino acid iso-
form (hepcidin-25) levels, which are directly responsible
for the biological effect, have not been documented and
factors that contribute to hepcidin regulation in this dis-
ease have not been assessed.
haematologica | 2009; 94(6) | 885 |
LETTERS TO THE EDITOR
Table 1. Characteristics of study populations of adult sickle cell disease patients in steady state of their disease.  
Gender Age Transfused Genotype BMI Hb MCV ALT Ferritin TS CRP sTfR Reticulocytes Hepcidin-25 Hepcidin-25
(M/F) (years) PCU Serum Urine Serum Urine
(n) (kg/m2) (mmol/L) (fL) (U/L) (µg/L) (0/0) (mg/L) (mg/L) (0/0) (nmol/L) (nmoL/ (pmol/ (pmol/
mmoL cr) µg) mmol 
cr.µg)
1 F 24 32 SS# 31.9 5.9 92.2 81 4470 39.5 50 7.79 11.00 5.5 1.7 1.2 0.4
2 M 22 15 SS# 19.4 6.0 − 21 213 71.7 5 8.93 − <LLOD 0.1 2.3 0.5
3 F 52 16 SS 23.9 5.4 118.01 23 2051 44.4 8 5.36 10.80 9.5 2.5 4.6 1.2
4 F 45 67 SS# 18.9 4.6 85.8 16 108 24.1 <5 5.85 8.80 <LLOD 0.1 4.6 0.9
5 F 18 2 SS# 21.1 6.0 96.2 16 140 42.6 <5 4.85 10.00 <LLOD 0.1 3.6 0.7
6 F 22 5 SS# 21.9 5.2 93.1 14 438 39.6 <5 7.69 19.20 1.5 0.3 3.4 0.7
7 F 33 51 SS 19.8 4.0 90.1 26 210 41.9 10 10.40 17.50 <LLOD 0.1 2.4 0.5
8 F 45 24 SS 18.0 6.1 99.9 68 739 23.3 <5 5.81 7.50 5.4 1.4 7.3 1.9
9 F 46 11 SS 31.3 5.2 125.01 10 293 31.2 12 6.14 13.10 2.4 0.4 8.2 1.4
10 F 19 8 Sβ0 22.5 5.4 64.2 52 180 25.5 10 6.87 8.30 1.2 0.5 6.7 2.8
11 F 41 43 Sβ0# 19.3 4.9 68.9 49 826 42.0 10 5.50 7.80 7.6 0.6 9.2 0.7
12 F 33 30 Sβ0 24.4 6.0 65.5 7 392 21.8 6 7.96 6.30 1.2 0.5 3.1 1.3
13 F 24 n.a. SC 21.2 5.9 74.7 7 40 23.5 <5 4.03 3.00 <LLOD 0.1 12.5 2.5
14 M 32 19 SC 27.6 8.6 85.7 26 91 32.8 <5 2.72 2.70 1.4 0.1 15.4 1.1
15 F 29 4 SC 22.8 6.6 73.1 13 65 21.6 <5 2.23 1.60 3.6 0.5 55.4 7.7
16 F 40 n.a. SC 24.2 7.3 71.1 6 49 18.5 <5 3.15 1.60 1.7 0.2 34.7 4.1
Med.n.a. 33 18 n.a. 22.2 5.9 85.8 19 212 32.0 10 5.83 8.30 1.5 0.4 5.7 1.2 
(range) (18-52) (0-67) (18.0- (4.0- (64.2- (6-81) (40- (18.5- (5-50) (2.23- (1.60- (<0.5-9.5) (0.1-1.7) (1.2-55.4) (0.4-7.7)
31.9) 8.6) 125.0) 4470) 71.7) 10.40) 19.20)
Control^
17 M 27 n.a. AS 26.4 7.8 93.0 16 219 58.5 <5 1.32 0.80 4.6 1.5 21.0 6.8
18 F 37 n.a. AS 36.3 7.2 65.3 18 66 19.4 22 1.21 1.10 6.0 0.1 90.9 1.5
19 F 61 n.a. AS 31.2 9.0 81.0 46 132 32.1 <5 1.32 1.00 3.9 2.7 29.6 20.5
20 M 42 n.a. AS 22.9 8.9 78.5 17 100 19.4 <5 1.40 0.90 5.8 1.4 58.0 14.0
21 F 27 n.a. AC 21.8 8.5 81.2 19 23 27.3 <5 0.85 0.70 1.4 0.2 60.9 8.7
22 F 38 n.a. AS 23.3 9.4 76.7 19 20 41.8 <5 2.27 2.20 0.7 0.3 35.0 15.0
23 F 25 n.a. AS 26.9 8.6 85.4 6 79 36.7 <5 0.76 1.70 1.8 1.5 22.8 19.0
Med. n.a. 37 n.a. n.a. 26.4 8.6 81.0 18 79 32.1 5 1.32 1.00 3.9 1.4 35.0 14.0 
(range) (25-61) (21.8- (7.2- (65.3- (6-46) (20- (19.4 (5-22) (0.76- (0.70- (0.7-6.0) (0.1-2.7) (21.0- (1.5-20.5)
36.3) 9.4) 93.0) 219) -58.5) 2.27) 2.20) 90.9)
1Patients 3 and 9 receive maintenance therapy with hydroxyurea; #,patients with co-inherited β-thalassemia; ^,these controls are race matched carriers and do not have anemia,enhanced
hemolysis or inflammation; -- indicates lab results are not available; n.a.not applicable; LLOD: lower limit of detection (0.5 nM).CRP is set <5 mg/L when there is no indication of inflammation.
Reticulocytes are expressed as the % reticulocytes of the population of red blood cells and reticulocytes.PCU,packed cell units; BMI: body mass index; Hb: hemoglobin; MCV: mean corpuscular
volume;ALT: alanine aminotransferase;TS: transferrin saturation; CRP: C-reactive protein; sTfR: soluble transferrin receptor, is a direct measure of the total transferrin receptor in the body and
reflects both the cellular need for iron and the rate of erythropoiesis; cr: creatinine.Reference range Caucasian controls hepcidin-25 (n=24),serum 0.5-13.9 nM and urine 0.01-10.6 nmol/mmol
creatinine (www.hepcidinanalysis.com); MCV 80-98 fL; serum TS female 15-50%,TS male 20-50%; ferritin female premenopasual 6-80 µg/L; ferritin female postmenopausal 6-190 µg/L; ferritin
male 15-280 µg/L; sTFR 0.76-1.76 mg/L.
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Samples were collected from adult steady state SCD
patients5 with various hemoglobin (Hb) genotypes (9
HbSS, 3 HbSβ0-thalassemia and 4 HbSC, Table 1)
between February 2005 and February 2006, and stored
in polypropylene tubes at –80°C until analysis. Patients
received no transfusions or chelation therapy for two
months prior to sampling. Race matched controls were
heterozygous for HbS or C.5 Serum and urinary hep-
cidin-25 measurements were performed in November
and December 2007 by use of surface enhanced laser
desorption ionization-time of flight mass spectrometry
(SELDI-TOF MS) as previously described.6,7 The hep-
cidin regulators’ inflammation, iron store and erythro-
poiesis (reflected in the serum markers C-reactive pro-
tein (CRP), ferritin and soluble transferrin receptor
(sTfR), respectively) were assessed to delineate the reg-
ulatory pathways of hepcidin.8 Approval for the study
was obtained from the Medical Ethics Committee of the
Academic Medical Center in Amsterdam. 
We found the various serum parameters to vary wide-
ly within this population (Table 1). Of note is the pat-
tern of the serum iron parameters, which shows highly
variable ferritin levels, not simply related to the transfu-
sion history and in the presence of normal transferrin
saturation (TS). This suggests an iron distribution pat-
tern of the anemia of chronic disease, with relatively
more iron in the RE system. 
Serum hepcidin-25 levels were below the lower limit
of detection (LLOD <0.5 nM) in 5 SCD patients, while
in the rest, the levels were between 1 and 10 nM, which
is considered to be the normal range (Table 1). The
median serum and urine hepcidin-25 levels were similar
for patients and controls (p>0.2), but hepcidin-25/fer-
ritin ratio’s as a measure of appropriateness of hepato-
cyte-produced hepcidin for the iron burden,4 were sig-
nificantly lower for patients (p<0.01) (Table 1).
However, as ferritin in SCD might be increased by
inflammation and iron loading of RE cells by transfu-
sions, this ratio might not be suitable in the evaluation
of the adequacy of hepcidin in response to hepatocyte
iron loading.9
Results confirm that erythropoiesis down-regulates
hepcidin-25, i.e. when only sTfR is increased, serum
hepcidin-25 levels are in the lower normal range or even
not detectable (<LLOD-3.6 nM; patients 2, 4, 5, 13-16).
In cases where next to a substantially increased sTfR
inflammation and/or high iron stores are also present,
serum hepcidin-25 levels are in the normal range (1.2 -
9.5 nM; patients 1, 3, 6, 8-12) confirming the induction
of hepcidin by inflammation and elevated iron stores in
sickle cell patients. Interestingly, in patient 7 the low
hepcidin-25 level due to increased erythropoiesis (high-
ly elevated sTfR) is not compensated by low grade
inflammation (CRP of 10 mg/L) and a slightly elevated
iron store (ferritin of 210 µg/L), resulting in undetectable
serum hepcidin-25 levels. 
While this is a small study, the results only describe
the qualitative contribution of the various parameters to
hepcidin-25 levels. Nevertheless, Spearman’s correla-
tion analysis showed that serum hepcidin-25 levels
were significantly correlated with urine hepcidin-25, log
ferritin, Body Mass Index (BMI)10 (Figure 1A-C) and age,
but not with CRP, sTfR, TS (Figure 1D-F) and hemoglo-
bin. 
In conclusion, this proof of principle study in a het-
erogeneous group of SCD patients indicates that: (i) pre-
vious results obtained in vitro and mice studies of hep-
cidin-25 suppression by increased erythropoietic activi-
ty that is counterbalanced by iron stores and (low grade)
inflammation are also valid in man; (ii) larger studies are
needed to determine the quantitative contribution of
various factors to hepcidin-25 regulation in this disease. 
The insights gained in this study could be clinically
beneficial in the identification and treatment of patients
most at risk of iron mediated tissue damage.
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Predictive value of β2-microglobulin (β2-m)
levels in chronic lymphocytic leukemia since
Binet A stages
We read with interest the study by Rossi and co-
workers, reporting CD49d expression as risk factor of
treatment free survival (TFS) in Binet A CLL patients.1 In
this paper, a close association between CD49d and
CD38, LDH and β2-m is also described. We would like
to add further information about the prognostic power
of β2-m. It is generally believed that β2-m is released
constitutively by CLL cells and that its level approxi-
mately correlates with tumor mass.2 Based on these
premises the predictive value of β2-m serum concentra-
tion could vary in the course of the disease and be rela-
tively low in the early disease stages, when tumor mass
is low, irrespective of the subsequent clinical outcome.
Therefore, β2-m determination could exhibit a lower
predictive power particularly at the early disease stages
compared to the newer biological markers, such as
IgVH gene status, ZAP-70 and CD38, which represent
intrinsic cell features that can be determined since the
earliest disease stages and never (IgVH) or rarely (ZAP-
70 and CD38) change in the course of the disease.3
In order to explore this issue, we have measured β2-
m value in 222 Binet stage A patients at diagnosis. IgVH
gene status and CD38 expression were also determined
in all cases studied. Unlike β2-m, which was measured
at diagnosis, these markers were determined in the
course of the disease when marker determinations
became available. This approach, although irrelevant for
the IgVH gene status, may introduce some, albeit minor,
biases for CD38 for the reasons alluded to above. The
median β2-m value was 2 mg/dL (range 0.4-19). ROC
analysis determined that the cut-off value capable of
discriminating between patients whose disease pro-
gressed and required treatment from those with stable
disease was 2.4 mg/dL (AUC:0.67, p=0.005).
Accordingly 149/222 patients (67%) were β2-mneg and
73/222 (33%) as β2-mpos. Overall, the results did not
substantially change when arbitrary cut offs used by
other authors4-7 were employed.
The patients’ features are summarized in Table 1. β2-
m levels overlap with CD38 expression in 128/219 cases
(63%) [β2-mpos/CD38≥30% cases: 23/55 (41.8%), β2-
mneg/CD38<30% cases: 115/164 (70.1%)], while β-m
levels overlap with IgVH status in 125/195 cases
(64.1%) [β2-mpos/IgVHunmutated cases: 29/62 (46.8%),
β2-mneg/IgVHmutated: 96/133 (72.2%)]. Finally, the con-
cordance between CD38 expression and IgVH muta-
tional status was 77.6% (149/192 cases)
[IgVHunmutated/CD38≥30% cases: 35/52 (67.3%),
IgVHmutated/CD38<30% cases: 114/140 (81.4%)]. 
After a median follow-up of 3.5 years, 55 of 222 Binet
stage A (25%) required treatment. β2-mneg cases showed
a significantly longer TFS than β2-mpos cases; in particu-
lar the projected median TFS was 5.3 years for β2-mpos
versus not reached for β2-mneg (Figure 1A). TFS repre-
sented a reliable measure of disease progression since all
centers agreed to follow NCI guidelines for treatment
start. 
In order to ascertain whether β2-m identifies a patient
subset of those with good prognostic markers, we calcu-
lated TFS of both CD38<30% and IgVHmutated CLL
cases grouped according to the β2-m expression. β2-mpos
CD38<30% cases exhibited a TFS which was signifi-
cantly lower than that of β2-mneg CD38<30% cases (3.5-
years TFS probability: β2-mneg vs. β2-mpos 91% vs. 83%;
p=0.05). However, these differences were not seen in
the IgVHmutated cases (3.5-years TFS probability: β2-
mneg vs. β2-mpos 89% vs. 84%; p=ns).
At Cox univariate analysis, β2-mpos (HR:2.3, p=0.003),
CD38>30% (HR:3.9, p<0.0001) and IgVHunmutated
(HR:3.2, p<0.0001) showed a statistically significant
impact on TFS. At Cox multivariate analysis, all the
three markers maintained an independent prognostic
impact (β2-mpos, HR:1.8, p=0.047; CD38>30%, HR:2.0,
p=0.03; IgVHunmutated, HR:2.7, p=0.022). When a
scoring system in which one point was assigned to each
unfavorable prognostic marker was utilized, the risk of
an early treatment was highest (Figure 1B) in patients
presenting all the three adverse prognostic markers.
Cases with two, one or none of the unfavorable prog-
nostic factors showed lower risk for an early treatment
(Figure 1C). 
Collectively, this study shows that β2-m levels repre-
sent valuable predictors in early CLL stages, when the
neoplastic cell burden is low. This finding raises a num-
ber of questions regarding the mechanisms governing
the β2-m levels. This molecule is constantly shedded8
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Table 1. Comparisons of clinical and laboratory features among
chronic lymphocytic leukemia patients devised according to β2-m
expression.
All patients β2-m <2.4 β2-m ≥2.4 p
mg/d mg/dL
N. of patients 222 149 (67) 73 (33)
Age (years) 
≤65 124 (56) 94 (63) 30 (41) 0.002
>65 98 (44) 55 (37) 43 (59)
Gender
Female 82 (37) 60 (40) 22 (30) 0.14
Male 140 (63) 99 (60) 51 (70)
IgVH mutational status (n=195)
Mutated 133 (68) 96 (74) 37 (56) 0.014
Germline 62 (32) 33 (26) 29 (44)
CD38 expression (n=219)
<30% 164 (75) 115 (78) 42 (58) 0.02
≥30% 55 (25) 32 (22) 30 (42)
Therapy
no 167 (75) 123 (83) 44 (60) <0.0001
yes 55 (25) 26 (17) 29 (40)
